Impact of clinical pharmacist mediated patient education on HbA1c and insulin adherence among diabetic population

Authors

  • A. Anusha Devi Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India
  • B. Pavani Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India
  • K. Bhanu Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India
  • Mohammed Thamijulla Khan Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India
  • D. V. Ramana Kumari Department of Diabetology at NRI Academy of Sciences General and Super Specialty Hospital, Chinnakakani, Andhra Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20263767

Keywords:

Clinical pharmacist, Diabetes mellitus, Insulin therapy, Medication adherence, Glycemic control, Patient education

Abstract

Background: To evaluate the association of structured clinical pharmacist-mediated patient education with glycemic control, medication adherence, and diabetes self-management among insulin-treated adults with diabetes mellitus.

Methods: A single-arm prospective cohort study was conducted from July 2024 to March 2025 among 70 adults with type 1 or type 2 diabetes mellitus receiving insulin therapy for at least three months at the Department of Diabetology, NRI Academy of Sciences General and Super Specialty Hospital, Chinakani, Andhra Pradesh, India. Participants received structured pharmacist-mediated education on diabetes self-management, insulin administration and storage, medication adherence, lifestyle modification, and self-monitoring of blood glucose, supported by a Patient Information Leaflet. HbA1c, fasting blood glucose (FBS), postprandial blood glucose (PPBS), MMAS-8, and DMSES were assessed at baseline and after three months. Continuous variables were summarized as mean ± SD and compared using paired Student’s t-tests; p<0.05 was considered statistically significant.

Results: Mean HbA1c decreased from 8.754±1.915% to 8.085±1.481% (reduction 0.669%; p=0.00013). FBS decreased by 18.274 mg/dL (p=0.0078), and PPBS decreased by 25.257 mg/dL (p=0.00187). MMAS-8 increased from 3.957±1.215 to 5.585±1.210 (p=0.00000127), while DMSES increased from 4.216±1.137 to 5.983±1.408 (p=0.00000189).

Conclusions: Pharmacist-mediated education was associated with improved glycemic parameters, medication adherence, and diabetes self-management self-efficacy. Due to the absence of a control group, findings represent pre-post associations rather than definitive causal effects.

Metrics

Metrics Loading ...

References

Magliano DJ, Boyko EJ; IDF Diabetes Atlas 11th edition scientific committee. IDF Diabetes Atlas. 11th ed. Brussels: International Diabetes Federation; 2025. Available from: https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/ Accessed on 28 May 2026.

Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932-8. DOI: https://doi.org/10.4103/ijo.IJO_1627_21

American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1-S326.

Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009;41(6):703-7. DOI: https://doi.org/10.1038/ng.381

Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001;358(9292):1500-3. DOI: https://doi.org/10.1016/S0140-6736(01)06580-1

Knip M, Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev. 2008;7(7):550-7. DOI: https://doi.org/10.1016/j.autrev.2008.04.008

Lamb MM, Myers MA, Barriga K, Zimmet PZ, Rewers M, Norris JM. Maternal diet during pregnancy and islet autoimmunity in offspring. Pediatr Diabetes. 2008 Apr;9(2):135-41. DOI: https://doi.org/10.1111/j.1399-5448.2007.00311.x

Noble JA, Erlich HA. Genetics of type 1 diabetes. Cold Spring Harb Perspect Med. 2012;2(1):a007732. DOI: https://doi.org/10.1101/cshperspect.a007732

Redondo MJ, Jeffrey J, Fain PR, Eisenbarth GS, Orban T. Concordance for islet autoimmunity among monozygotic twins. N Engl J Med. 2008;359(26):2849-50. DOI: https://doi.org/10.1056/NEJMc0805398

Yeung WC, Rawlinson WD, Craig ME. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ. 2011;342:d35. DOI: https://doi.org/10.1136/bmj.d35

Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473-9. DOI: https://doi.org/10.1001/jama.2013.6285

Todd JA. Etiology of type 1 diabetes. Immunity. 2010;32(4):457-67. DOI: https://doi.org/10.1016/j.immuni.2010.04.001

Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38(3):320-3. DOI: https://doi.org/10.1038/ng1732

Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-6. DOI: https://doi.org/10.1038/nature05482

Lyssenko V, Laakso M. Genetic screening for the risk of type 2 diabetes. Diabetes Care. 2013;36(Suppl 2):S120-6. DOI: https://doi.org/10.2337/dcS13-2009

Prentki M, Nolan CJ. Islet β-cell failure in type 2 diabetes. J Clin Invest. 2006;116(7):1802-12. DOI: https://doi.org/10.1172/JCI29103

Weir GC, Bonner-Weir S. Five stages of beta-cell dysfunction during diabetes progression. Diabetes. 2004;53(Suppl 3):S16-21. DOI: https://doi.org/10.2337/diabetes.53.suppl_3.S16

American Heart Association. Diabetes complications and risks. Dallas (TX): American Heart Association; 2026 [reviewed 2026]. Available from: https://www.heart.org/en/health-topics/diabetes/diabetes-complications-and-risks Accessed on 28 May 2026.

Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action. Circulation. 2006;113(25):2943-6. DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.176583

Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016;26(4):364-73. DOI: https://doi.org/10.1016/j.tcm.2015.10.004

American Diabetes Association Professional Practice Committee for Diabetes. 6. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S132-49. DOI: https://doi.org/10.2337/dc26-S006

American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S183-S215. DOI: https://doi.org/10.2337/dc26-S009

Klonoff DC, Berard L, Franco DR, Gentile S, Gomez OV, Hussein Z, et al. Advance insulin injection technique and education with FITTER Forward expert recommendations. Mayo Clin Proc. 2025;100(4):682-99. DOI: https://doi.org/10.1016/j.mayocp.2025.01.004

Kalra S, Unnikrishnan AG, Prasanna Kumar KM, Sahay R, Chandalia HB, Saboo B, et al. Addendum 1: Forum for Injection Technique and Therapy Expert Recommendations, India. Diabetes Ther. 2023;14:29-45. DOI: https://doi.org/10.1007/s13300-022-01332-x

Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviors and barriers. Diabet Med. 2012;29(5):682-9. DOI: https://doi.org/10.1111/j.1464-5491.2012.03605.x

Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299-307. DOI: https://doi.org/10.2147/PPA.S106821

Ali MS, Alshayban DM, Almogbel YS, Alanzi TM, Alhazmi RH, Alotaibi AM. Factors influencing insulin adherence among outpatients with type 2 diabetes mellitus. J Diabetes Res. 2024;2024:5518977.

Wang L, Zhang Y, Wei Q, Liang X, Zhou J, Ma A, et al. The effect of pharmacist intervention on medication adherence measured with proportion of days covered: a systematic review and meta-analysis. Int J Clin Pharm. 2025;47(6):1590-608. DOI: https://doi.org/10.1007/s11096-025-01974-4

World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. Available from: https://iris.who.int/handle/10665/42682 Accessed on 28 May 2026.

Lee EH, van der Bijl J, Shortridge-Baggett LM, Han SJ, Moon SH. Psychometric properties of the Diabetes Management Self-Efficacy Scale in Korean patients with type 2 diabetes. Int J Endocrinol. 2015;2015:780701. DOI: https://doi.org/10.1155/2015/780701

Abdulrhim S, Sankaralingam S, Ibrahim MI, Awaisu A. The impact of pharmacist care on diabetes outcomes in primary care settings: an umbrella review of published systematic reviews. Prim Care Diabetes. 2020;14(5):393-400. DOI: https://doi.org/10.1016/j.pcd.2019.12.007

Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the ADA and EASD. Diabetes Care. 2018;41(12):2669-701. DOI: https://doi.org/10.2337/dci18-0033

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S140-57. DOI: https://doi.org/10.2337/dc23-S009

Ihekoronye MR, Osemene KP, Oamen TE. Pharmacist-led intervention to improve treatment outcomes in type 2 diabetes: a randomized controlled trial. J Pharm Health Serv Res. 2024;15(2):rmae005. DOI: https://doi.org/10.1093/jphsr/rmae005

Twisdale C, Land D, Robinson A. Diabetes outcomes of patients followed by pharmacists newly embedded in primary care clinics. Am J Health Syst Pharm. 2026;83(Suppl 4):S2989-94. DOI: https://doi.org/10.1093/ajhp/zxaf356

Selvadurai S, Cheah KY, Ching MW, Mohd Ali LM. Impact of pharmacist insulin injection re-education. Saudi Pharm J. 2021;29(8):666-72. DOI: https://doi.org/10.1016/j.jsps.2021.04.028

Zhang L, Lin H, Wu W, Zhuang J, Huang L, Wang Y, et al. A meta-analysis of the impact of pharmacist interventions on clinical outcomes in patients with type-2 diabetes. Patient Educ Couns. 2024;120:108091. DOI: https://doi.org/10.1016/j.pec.2023.108091

Ahmad K, Anchah L, Ting CY, Lim SE. Effectiveness of a pharmacist-led, community group-based education programme in enhancing diabetes management: a multicentre randomised control trial. Contemp Clin Trials Commun. 2024;38:101280. DOI: https://doi.org/10.1016/j.conctc.2024.101280

Mehta P, Kiruthika S, Laksham KB. Effectiveness of health education on insulin injection technique in patients with type 2 diabetes mellitus: a quasi-experimental pre-test post-test research. J Family Med Prim Care. 2024;13(11):5101-7. DOI: https://doi.org/10.4103/jfmpc.jfmpc_543_24

Cani CG, Lopes LSG, Queiroz M, Nery M. Improvement in medication adherence and self-management of diabetes with a clinical pharmacy program: a randomized controlled trial in patients with type 2 diabetes undergoing insulin therapy at a teaching hospital. Clinics (Sao Paulo). 2015;70(2):102-6. DOI: https://doi.org/10.6061/clinics/2015(02)06

Xin C, Xia Z, Jiang C, Lin M, Li G. Effect of pharmaceutical care on medication adherence of patients newly prescribed insulin therapy: a randomized controlled study. Patient Prefer Adherence. 2015;9:797-802. DOI: https://doi.org/10.2147/PPA.S84411

Laghousi D, Rezaie F, Alizadeh M, Asghari Jafarabadi M. The eight-item Morisky Medication Adherence Scale: validation of its Persian version in diabetic adults. Caspian J Intern Med. 2021;12(1):77-83.

Downloads

Published

2026-10-26

How to Cite

Devi, A. A., Pavani, B., Bhanu, K., Khan, M. T., & Kumari, D. V. R. (2026). Impact of clinical pharmacist mediated patient education on HbA1c and insulin adherence among diabetic population . International Journal of Basic & Clinical Pharmacology, 15(6), 1177–1186. https://doi.org/10.18203/2319-2003.ijbcp20263767

Issue

Section

Original Research Articles